Publications by authors named "Muhammad M Shoaib"

Article Synopsis
  • Dementia is a growing global healthcare challenge, impacting memory and social abilities while necessitating targeted interventions based on mortality trends and high-risk populations.
  • An analysis of CDC WONDER data from 1999-2020 revealed over 4 million dementia-related deaths in the U.S., predominantly from Alzheimer's disease and unspecified dementia, with notable differences in mortality rates based on demographics and geography.
  • The age-adjusted mortality rates showed a steep increase from 1999 to 2010, followed by a slower rise until 2020, with females and non-Hispanic whites experiencing the highest rates, while the lowest were found among non-Hispanic Asians or Pacific Islanders.
View Article and Find Full Text PDF

Degradable low-fouling hydrogels are ideal vehicles for drug and cell delivery. For each application, hydrogel degradation rate must be re-optimized for maximum therapeutic benefit. We developed a method to rapidly and predictably tune degradation rates of low-fouling poly(oligo(ethylene glycol)methyl ether methacrylate) (P(EG) MA) hydrogels by modifying two interdependent variables: (1) base-catalysed crosslink degradation kinetics, dependent on crosslinker electronics (electron withdrawing groups (EWGs)); and, (2) polymer hydration, dependent on the molecular weight ( ) of poly(ethylene glycol) (PEG) pendant groups.

View Article and Find Full Text PDF

Poly(carboxybetaine) (pCB) hydrogels do not elicit a foreign body response due to their low-fouling properties, making them ideal implantable materials for in vivo drug and cell delivery. Current reported pCB hydrogels are cross-linked using cytotoxic UV-initiated radical polymerization limiting clinical and in vivo translation. For clinical translation, we require in situ and biorthogonal cross-linking of pCB hydrogels that are both low-fouling and low-swelling to limit nonspecific interactions and minimize tissue damage, respectively.

View Article and Find Full Text PDF

Antibodies are a growing class of cancer immunotherapeutics that facilitate immune-cell-mediated killing of tumors. However, the efficacy and safety of immunotherapeutics are limited by transport barriers and poor tumor uptake, which lead to high systemic concentrations and potentially fatal side effects. To increase tumor antibody immunotherapeutic concentrations while decreasing systemic concentrations, local delivery vehicles for sustained antibody release are being developed.

View Article and Find Full Text PDF